Kornimate/medical-research-clean huggingface dataset:
cryo-ablation to treat patients with hocm.

Conditions: HOCM, Hypertrophic Obstructive Cardiomyopathy

Summary: the purpose of the study is to perform endocardial catheter cryo-ablation to relieve the lvot obstruction in patients with hypertrophic obstructive cardiomyopathy. the investigators hypothesize that the investigators will be able to reduce \> 50% of the initial lvot gradient. this will be considered as a successful procedure.


Eligibility criteria:
inclusion criteria: 1. the patient must be ≥18 years of age 2. the patient has left ventricular outflow tract obstruction with hypertrophic obstructive cardiomyopathy 3. the patient is on optimal medication 4. the patient is not eligible for/failed/refused alcohol ablation 5. the patient is not eligible for/failed/refused myectomy 6. the patient is willing to participate in the study and has signed informed consent 7. the patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved be the appropriate medical ethics committee. exclusion criteria: 1. pregnant or nursing patients female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test 2. patient has history of or known impaired renal function (serum creatinine \>2.0 mg/dl or 177 µmol/l) or on dialysis 3. patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated 4. patient has a known hypersensivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel and/or contrast sensitivity/allergy that cannot be adequately pre-medicated 5. patient has other medical illness not related to the hypertrophic cardiomyopathy (e.g., cancer, known malignancy, or cognitive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than 1 year) 6. subject is enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by the investigator, during the course of this clinical study 7. subjects meets the exclusion criteria required by local low (e.g. age, pregnancy, breast-feeding, etc) 8. subject is anticipated not being able to complete the study

Keywords: cryo ablation cardiomyopathy
treating avoidant/restrictive food intake disorder (arfid) using family-based treatment

Conditions: Avoidant / Restrictive Food Intake Disorder

Summary: although avoidant/restrictive food intake disorder (arfid) was formally introduced in dsm-5, no specialized intervention has yet been empirically studied. this randomized controlled crossover trial (rcct) will test the feasibility and acceptability of a novel intervention, family-based treatment of avoidant/restrictive food intake disorder (fbt-arfid) for patients ages 5-12 years old.

potential subjects aged 5 years to 12 years, 11 months old with anorexia nervosa (an) diagnosed with arfid and their families will be recruited will be recruited through stanford university, pediatricians, mental health experts, clinics treating eds, and local parents' groups. those eligible for the program will be invited to read and sign informed consent forms and complete the baseline assessment. they will then be randomized to the fbt-arfid program either immediately after their screening or 3 months after assessment (i.e., to a usual care group). fbt-arfid consists of 22 sessions over a 6-month period. there will be 3 major assessment time points for those in the fbt-arfid arm: baseline, 3 months into treatment, and eot. there will be 4 major assessment time points for those in usual care: baseline, transition to treatment (3 months after the usual care period is complete), 3 months into treatment, and eot. both the child and the parent will complete measures at these time points. in addition, patients and parents will participate in ongoing qualitative assessments before treatment (bl), throughout treatment (every other session), and at eot.

Eligibility criteria:
inclusion criteria: * children meeting dsm-v criteria for arfid * children between the ages of 5 to 12 years old exclusion criteria: * any medical complications or severe mental disorder (psychosis, low-functioning autism) that may reduce compliance with the study procedures or require more intensive care to manage the symptoms * a severe parental mental disorder (e.g., psychotic depression, psychosis, substance dependence)
myeloid-derived suppressor cell function in breast cancer patients

Conditions: Breast Cancer

Summary: myeloid-derived suppressor cell function in breast cancer patients


Eligibility criteria:
inclusion criteria: * 18 years of age or older * ability to give informed consent * stage i-iii breast malignancy exclusion criteria: * unable to tolerate venipuncture
propel-2: prophylactic negative pressure wound therapy in laparotomy wounds

Conditions: Wound Surgical; Wound Infection; Cosmesis

Summary: post-operative wound issues in abdominal surgery have a significant impact on patient outcomes. this study is taking place to investigate if negative pressure wound therapy (npwt) dressings reduces surgical site infections, post surgical complications and improves scar appearance compared to standard dressings.

npwt dressings are designed to remove and absorb any fluid leaking from the wound. this might reduce surgical site infections, improve wound healing and improve scar appearance compared to using standard dressings. data is limited in the application of npwt dressings to laparotomy incisions in the acute and elective care surgery setting. surgical site infections can complicate a patient's post-operative course significantly, often necessitating a longer length of stay, antibiotic therapy, intervention for wound collections and impair patient mobility and overall recovery. in addition to this, laparotomy wound complications can possibly delay adjuvant therapy and also increases healthcare costs both as an inpatient and in the community. despite significant measures to reduce such complications in the form of wound care bundles, changing of gloves prior to wound closure etc., surgical site complications continue to represent a huge healthcare burden. the investigators are conducting this study to determine whether npwt dressings reduce surgical site infections, improve wound healing and scar appearance. this study will also involve a cost-based analysis and seek information from patients on their quality of life. results from this study will provide evidence on whether these dressings should be used as standard of care for management of surgical laparotomy wounds.

Eligibility criteria:
inclusion criteria: * aged 18 years or older * patient requires visceral abdominal surgery via a midline laparotomy * patients who can complete questionnaires exclusion criteria: • patients who are unable to adhere to protocol requirements

Keywords: negative pressure wound therapy surgical site infection laparotomy post-operative complications abdominal incision health economics posas copaq
sleep respiratory disorders in patients with moderate to severe persistent rhinitis

Conditions: Rhinitis

Summary: the general aim of this study is to demonstrate that the measurement of respiratory effort assessed by mandibular movements during sleep is a useful measure for the screening of sleep disordered breathing (sdb) in patients with moderate to severe persistent rhinitis (r). the primary objective is therefore to determine a mandibular movement respiratory disturbance index (mm-rdi) threshold associated with a polysomnography respiratory disturbance index (psg-rdi) ≥ 15 / h in a population of patients with moderate-to-severe persistent r.

the secondary objectives of the study are to evaluate the concordance and correlation between: * mm-rdi, * the respiratory effort evaluated by mm, * polysomnography (psg) results, * quality of life questionnaires, * clinical data, * treatments.

Eligibility criteria:
inclusion criteria: * patient consulting for persistant, moderate-to-severe rhinitis * the patient has signed the informed consent * the patient is a beneficiary of a social security programme (national health insurance) * patient living in the montpellier region (\< 30 kilometers). exclusion criteria: * the patient is participating in another study that precludes participation in the present study * the patient is in an exclusion period determined by another study * it is impossible to correctly inform the patient * the patient cannot fluently read french * vulnerable patient populations according to french health code article l1121-6 * adult under guardianship or incapable of giving consent according to french health code article l1121-8 * pregnancy, breastfeeding (french health code article l1121-5) * any element that renders participation in the study problematic according to the investigator
infections and latent autoimmune diabetes in adults

Conditions: Latent Autoimmune Diabetes in Adults; Type 2 Diabetes

Summary: infections are proposed risk factors for type 1 diabetes in children. the investigators will examine whether a diagnosis of infectious disease also confers an increased risk of latent autoimmune diabetes in adults.

the investigators will use data from a population-based swedish case-control study (estrid) with incident cases of lada (n=597) and matched controls (n=2386). history of infectious disease are ascertained through national and regional patient registers. the investigators will estimate adjusted odds ratios (or) with 95% ci for ≥1 respiratory (any/upper/lower), gastrointestinal, herpetic, other or any infectious disease episode, or separately, for 1 and ≥2 infectious disease episodes, within 0-1, 1-3, 3-5 and 5-10 years before lada diagnosis/matching. stratified analyses will be performed based on hla risk genotypes and gada levels.

Eligibility criteria:
inclusion criteria: * 35 years or older, residing in scania or uppsala county. exclusion criteria: * less than 35 years

Keywords: latent autoimmune diabetes in adults infections diabetes mellitus type 2 diabetes case-control studies register study
comparison of anatomically aligned and conventional total knee arthroplasty in the same patients

Conditions: Knee Osteoarthritis; Anatomically Aligned Total Knee Arthroplasty

Summary: total knee arthroplasty(tka) is a successful orthopedic surgery with excellent clinical outcome and survival. however, there are concerns about patient satisfaction in previous reports, and dissatisfaction rate of 15-30% is reported in clinical outcomes(proms) of some studies. therefore, for improving the patient's outcome and satisfaction after total knee arthroplasty, it is necessary to change the design of the conventional total knee arthroplsaty implant. the knee is a joint structure with several dynamic functions, and not only the skeletal structure but also the soft tissue balance plays an important role in the function of the knee joint. new implants are being developed to overcome the limitations of conventional tka implant, including the journey ii bi-cruciate substituting total knee system (jii-bcs; smith \& nephew). jii-bcs implant has normal articular geometry, more anatomical femoral shape, lateral tibial convex geometry, and asymmetrical tibial plateau, anterior and posterior cams, which has been shown in experimental studies to produce nearly normal knee movement by reproducing the actual normal anatomical alignment in vivo. the clinical results of the kinematic effects of this anatomcally aligned change are insufficient, and there is also a lack of comparative studies with conventional total knee arthroplasty implant. the purpose of this study is to compare outcomes between anatomically aligned tka(jii-bcs) and conventional tka(legion total knee system, smith \& nephew). this study is a randomized controlled study in patients undergoing total knee arthroplasty per day. radiologic parameter, patients preference and clinical results was investigated in both knee of same patients who received tka during minimum 2 year follow up.


Eligibility criteria:
inclusion criteria: * patients for bilateral total knee arthroplasty * having medicare insurance exclusion criteria: * rheumatoid arthritis * other inflammatory arthritis * crystal-induced arthritis * septic arthritis * neuropsychiatric patients * previous knee operation history * neuropsychiatric patients * patients with preoperative severe limitation of motion (flexion contracture ≥ 20, range of motion ≤ 90) * patients with preoperative severe defomity of knee alignment (varus or valgus angle ≥ 15) * severe obese patients (bmi ≥ 40)
three-dose regimen of mrkad5+6 trigene (v526) in healthy adults (v526-001)(completed)

Conditions: HIV; HIV Infections

Summary: a study to assess the general safety and tolerability of the administration of the 3-dose regimen of the mrkad5+6 trigene vaccine


Eligibility criteria:
inclusion criteria: * subject has negative tests for hiv, hepatitis b, and hepatitis c within 60 days of injection * subject agrees to use an acceptable method of birth control through week 52 of the study exclusion criteria: * subject has been given immune globulin or blood products within 30 days of first dose of study vaccine * subject has been vaccinated with a live virus vaccine within 30 days or an inactivated vaccine within 5 days of first dose of study vaccine * subject has known or suspected impaired immune function * subject has participated in any other hiv vaccine trial * female subject is pregnant or breastfeeding

Keywords: hiv hiv seronegativity preventive vaccine
prospective cohort study for the real - life effectiveness evaluation of glycopyrronium with indacaterol combination in the management of copd in canada (power study)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this is a single cohort, prospective post approval study conducted on patients with copd in canada. the study will enroll patients that have not responded to their current treatment of tiotropium alone, or who are on the fixed dose combinations fluticasone propionate/salmeterol. only patients for whom the physician has decided to change treatment due to lack of efficacy will be eligible to be enrolled in the study. also will evaluate the real-life effectiveness of qva149 (indacaterol 110 mcg/glycopyrronium 50 mcg) in the management of patients.


Eligibility criteria:
inclusion criteria: * patient diagnosed and treated for moderate to severe copd according to the global initiative for chronic obstructive lung disease according to physician's assessment * smoking history of \> 10 pack - years. * on-going treatment with tiotropium or fixed dose combination of laba/ics, specifically combinations fluticasone propionate/salmeterol for a minimum of three months but demonstrating persistence of symptoms indicating change of treatment to combination therapy \*\*using a cat score \> 10. * treatment with qva149 is indicated as per the product monograph and appropriate for the patient as per the judgment of the treating physician. * patient has signed informed consent agreeing to participate in the study and undergo the study treatments and allowing the use of their data for the purposes of the study. * patient is expected to be available for 16 weeks after study enrolment * assessed as per routine care or as documented in the patient's chart. \*\* as determined and decided by the treating physician prior to enrolment of the patient in the study. exclusion criteria: patients fulfilling any of the following criteria are not eligible for inclusion in this study. no additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients. * patients not willing to sign an informed consent. * patient on maintenance treatment including triple therapy (laba +lama+ics) for copd * patients with a diagnosis of asthma or history of asthma. * patients who have had two or more moderate to severe exacerbations during the last 12 months prior to study enrolment. a moderate copd exacerbation is defined by requirement for treatment with systemic corticosteroids or antibiotics or both. a severe copd exacerbation is defined by hospitalization, including an emergency room visit of longer than 24 h. * patients who had an exacerbation within the previous 6 weeks to enrolment. * patients who as per physician clinical judgment will require ics treatment co-administered with qva149 during the study period. * patients with other chronic respiratory conditions that may affect the outcome of treatment including but not limited to lung cancer.

Keywords: copd, qva149, tiotropium, fdc, glycopyrronium with indacaterol, power
efficacy of prazosin in preventing post-traumatic stress disorder

Conditions: Acute Stress Disorder

Summary: after a traumatic event such as an accident or an assault, victims may experience intense stress symptoms that may evolve into "post-traumatic stress disorder" (ptsd). it is a frequent and serious pathology, which can be complicated by depression, addiction or suicide. few means are available to prevent ptsd in people who have just undergone trauma. prazosin is an antihypertensive drug that blocks α1 adrenaline receptors which could help to stop the vicious circle of stress and prevent the development of the disease. the objective of this study is to demonstrate the efficacy of prazosin to prevent ptsd in patients who visit an emergency department after trauma.


Eligibility criteria:
inclusion criteria: * patient of age \>18 years and \<65 years * victim of direct experience trauma (accident or physical aggression) * presence of an asd between d3 and d7 after the trauma according to dsm v criteria exclusion criteria: * contra-indication to prazosin: orthostatic hypotension, right heart failure, other hypotensive therapy, 5-phosphodiesterase inhibitors (sildenafil) or diuretic, history of syncope or severe unexplained faintness, hypersensitivity known to quinazolines. * alcohol and / or drug use at the time of the trauma * history of psychotic disorder * suicidal risk defined by a score ≥ 2 on the suicidal ideas item of the beck depression inventory (bdi) * protected or vulnerable major * persistence of a life threatening injury at d3 * sexual assault * only moderate head trauma can be included and therefore excluded patients with loss of consciousness greater than 30 minutes, glasgow score less than 13, post-traumatic amnesia greater than 24 hours (ruff et al., 2009) . * prescription of morphine or morphine derivative in progress * pregnancy or breastfeeding period * lack of effective contraception in a woman susceptible to childbearing * known hepatic dysfunction * narcolepsy (gelineau's disease) * cardiac or vascular history including coronary artery disease * strict low-sodium diet

Keywords: acute stress disorder post traumatic stress disorder prevention trauma prazosin
plasma vitamin and homocysteine levels and thrombosis in patients with ph-negative mpns

Conditions: Thrombosis

Summary: hyperhomocysteinemia is a risk for thrombosis. thrombosis is more frequent in myeloproliferative neoplasms (mpns) than the normal population. in this study, we investigated the thrombosis incidence, the effects of plasma homocysteine levels on thrombosis, and the correlations between folate, cobalamin, pyridoxine and homocysteine levels in mpns, and to compare these results with the healthy controls.

thirty-one new or formerly diagnosed mpn patients who consecutively visitted our outpatient clinic, as well as 40 age and sex matched healthy controls were enrolled in this study.

Eligibility criteria:
inclusion criteria: adult mpn patients and healthy controls who gave a written consent were included in the study. exclusion criteria: exclusion criteria included not giving a written consent and using medications without an indication which may have an effect on plasma homocysteine and vitamin levels.

Keywords: the incidence of thrombosis, the effect of hcy on thrombosis formation, the relation between hcy and plasma vitamin levels, to compare these results with the control group
cannabis cigarettes used for doping: delta-9-tetrahydrocannabinol (thc) urine detection

Conditions: Healthy

Summary: the purpose of this study on volunteers is whether thc and short-living metabolites are suited to detect recent cannabis smoking within urine doping control.

about half of all positive doping cases in switzerland have been related to cannabis consumption (mainly recreational smoking). so far, the target analyte in urine is 11-nor-9-carboxy-thc (thc-cooh), the main metabolite of delta-9-tetrahydrocannabinol (thc), which is excreted up to several days after single use. however, the wide detection window of thc-cooh does not allow a conclusion concerning the impact on the physical performance. therefore, the evaluation of other target analytes with shorter elimination half-lives is needed and the aim (primary endpoints) of the present study. this pharmacokinetic, open, 1-session trial on 12 healthy, male, infrequently cannabis smoking volunteers is focussed on the gc/ms profiling of thc and metabolites in urine and plasma after standardized smoking of a single 7% thc cannabis cigarette of the dutch ministry of health, welfare \& sport, office of medicinal cannabis. pharmacodynamic measurements (secondary endpoints) include the side-effects monitoring by using visual analog scales and checking vital functions.

Eligibility criteria:
inclusion criteria: * healthy male subjects; light (max. 1/month), infrequent cannabis smokers, medium (max. 15/month) tobacco smokers experienced in the inhalation technique; age 20-30 years; body weight 75+/-15 kg; evaluation based on normal medical history, physical examination, laboratory tests (safety lab), normal lung functions (spirometry). * informed consent after information (written) by the study physician and principal investigator on nature, significance and scope of the trial. * informed consent by the volunteer regarding transmitting trial-related data to the sponsor and to the competent control authorities. exclusion criteria: * hypersensitivity to cannabinoids. - regular (more than once per month, weekly or daily) cannabis use. - the use of alcohol, any medication or drugs, especially cannabis, within the last 2 days prior to and during the 1-day session is not allowed. cannabis use is also not allowed during the following 11 days of urine collection, i.e. up to the end of the study. * positive cannabis urine test before the session. * driving any vehicle, and operating with machines during and within 48 h after the session. * psychotic or vulnerable subjects.

Keywords: cannabis doping thc gc/ms pharmacokinetics volunteers